Cabergoline-d<sub>6</sub>

Cabergoline-d6

CAT N°: 31690
Price:

From 257.00 218.45

Cabergoline-d6 is intended for use as an internal standard for the quantification of cabergoline (Item No. 23934) by GC- or LC-MS. Cabergoline is a dopamine D2 receptor agonist (Ki = 0.912 nM in rat striatal homogenates).{41336} It is selective for dopamine D2 over D1 receptors (Ki = 6,935 nM). Cabergoline inhibits prolactin secretion in, and growth of, isolated rat pituitary tumor cells in a concentration-dependent manner, an effect that can be blocked by the dopamine D2 receptor antagonist haloperidol (Item No. 12014).{41337} Cabergoline reduces phosphorylation of mammalian target of rapamycin (mTOR) and induces the formation of LC3 puncta, a marker of autophagy, and apoptosis in MMQ rat pituitary cells.{41338} In vivo, cabergoline (0.25 mg/kg) stimulates motor activity and decreases dyskinesias in a cynomolgus monkey model of Parkinson’s disease induced by MPTP.{41339} Formulations containing cabergoline have been used in the treatment of prolactinomas.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • (6aR,9R,10aR)-7-allyl-N-(3-(bis(methyl-d3)amino)propyl)-N-(ethylcarbamoyl)-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxamide
  • Correlated keywords
    • GCMS LCMS deuturium deuterated D 1 2 m TOR LC 3
  • Product Overview:
    Cabergoline-d6 is intended for use as an internal standard for the quantification of cabergoline (Item No. 23934) by GC- or LC-MS. Cabergoline is a dopamine D2 receptor agonist (Ki = 0.912 nM in rat striatal homogenates).{41336} It is selective for dopamine D2 over D1 receptors (Ki = 6,935 nM). Cabergoline inhibits prolactin secretion in, and growth of, isolated rat pituitary tumor cells in a concentration-dependent manner, an effect that can be blocked by the dopamine D2 receptor antagonist haloperidol (Item No. 12014).{41337} Cabergoline reduces phosphorylation of mammalian target of rapamycin (mTOR) and induces the formation of LC3 puncta, a marker of autophagy, and apoptosis in MMQ rat pituitary cells.{41338} In vivo, cabergoline (0.25 mg/kg) stimulates motor activity and decreases dyskinesias in a cynomolgus monkey model of Parkinson’s disease induced by MPTP.{41339} Formulations containing cabergoline have been used in the treatment of prolactinomas.

We also advise you